Pharmafile Logo
Pharmafocus logo
Advanced Search

ulcerative colitis

Showing 6 posts of 36 posts found.

pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

News
Celgene

Celgene to acquire Receptos in $7.2bn deal

July 15, 2015
Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis

Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …

News
pfizer image

Pfizer teams up with Google-backed 23andMe

August 13, 2014
Research and Development, Sales and Marketing 23andME, Crohn’s disease, Pfizer, google, ulcerative colitis

Pfizer and genetics testing firm 23andMe have come together in a research pact aimed at finding the genetic cause of …

News
Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

News

Humira gains European licence for ulcerative colitis

April 11, 2012
Sales and Marketing Humira, ulcerative colitis

Abbott’s Humira has gained European approval to treat ulcerative colitis, adding to its six existing licences.   It can now …

News

Ulcerative colitis market set to double by 2018

February 12, 2010
Sales and Marketing Humira, Simponi, TNF, ulcerative colitis

The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026